Senzagen
  • Home
  • Services
    • GARDskin
    • GARDair
    • GARDpotency
    • Pipeline/Projects
  • Science
    • GARD® technology
    • Science behind
    • Scientific publications
    • Application notes
    • Posters
  • About
    • Board of directors
    • Career
    • Management
  • Partners
  • Investors
    • Aktien och aktieägare
    • Bolagsstyrning
    • Pressmeddelanden
    • Prospekt & Listning Nasdaq First North
    • Rapporter och finansiell information
  • News and Events
    • Event Calendar
    • News posts
    • Press releases
  • Contact
  • Search
  • Menu

1eafa40012976df2f66869619c8e41c0.jpeg

18 November, 2017/by

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Linkedin
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://senzagen.com/wp-content/uploads/2017/01/LoggaSquare_RGB_liten_HF.png 0 0 https://senzagen.com/wp-content/uploads/2017/01/LoggaSquare_RGB_liten_HF.png 2017-11-18 10:10:072017-11-18 10:10:071eafa40012976df2f66869619c8e41c0.jpeg

Choose a specific category

  • Application Notes
  • Distributors
  • Events
  • Financial events
  • GARDair
  • GARDpotency
  • GARDprotein
  • GARDskin
  • Licence laboratories
  • News/posts
  • Posters
  • Press releases – English
  • Pressmeddelanden – Svenska
  • Scientific publications

Archive

Follow us


Follow @SenzagenAb

Contact Us

SenzaGen AB, Medicon Village
Scheelevägen 2
223 81 Lund, Sweden

Phone: +46 46 2756200
Email: info@senzagen.com

Pages

  • Hem
  • Services
  • Science
  • About
  • Partners
  • Investors
  • Contact
  • News and Events

Follow Us



Follow @SenzagenAb

Scroll to top